Skip to main content
Top
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Human Papillomavirus | Research

Genomic alterations related to HPV infection status in a cohort of Chinese prostate cancer patients

Authors: Bin Lang, Chen Cao, Xiaoxiao Zhao, Yi Wang, Ying Cao, Xueying Zhou, Tong Zhao, Yuyan Wang, Ting Liu, Wenjia Liang, Zheng Hu, Xun Tian, Jingjing Zhang, Yongji Yan

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Background

Human papillomavirus (HPV) has been proposed as a potential pathogenetic organism involved in prostate cancer (PCa), but the association between HPV infection and relevant genomic changes in PCa is poorly understood.

Methods

To evaluate the relationship between HPV genotypes and genomic alterations in PCa, HPV capture sequencing of DNA isolated from 59 Han Chinese PCa patients was performed using an Illumina HiSeq2500. Additionally, whole-exome sequencing of DNA from these 59 PCa tissue samples and matched normal tissues was carried out using the BGI DNBSEQ platform. HPV infection status and genotyping were determined, and the genetic disparities between HPV-positive and HPV-negative PCa were evaluated.

Results

The presence of the high-risk HPV genome was identified in 16.9% of our cohort, and HPV16 was the most frequent genotype detected. The overall mutational burden in HPV-positive and HPV-negative PCa was similar, with an average of 2.68/Mb versus 2.58/Mb, respectively, in the targeted whole-exome region. HPV-negative tumors showed a mutational spectrum concordant with published PCa analyses with enrichment for mutations in SPOP, FOXA1, and MED12. HPV-positive tumors showed more mutations in KMT2C, KMT2D and ERCC2. Copy number alterations per sample were comparable between the two groups. However, the significantly amplified or deleted regions of the two groups only partially overlapped. We identified amplifications in oncogenes, including FCGR2B and CCND1, and deletions of tumor suppressors, such as CCNC and RB1, only in HPV-negative tumors. HPV-positive tumors showed unique deletions of tumor suppressors such as NTRK1 and JAK1.

Conclusions

The genomic mutational landscape of PCa differs based on HPV infection status. This work adds evidence for the direct involvement of HPV in PCa etiology. Different genomic features render HPV-positive PCa a unique subpopulation that might benefit from virus-targeted therapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
go back to reference Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584–90.CrossRefPubMed Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584–90.CrossRefPubMed
3.
go back to reference Moghoofei M, Keshavarz M, Ghorbani S, Babaei F, Nahand JS, Tavakoli A, et al. Association between human papillomavirus infection and prostate cancer: a global systematic review and meta-analysis. Asia Pac J Clin Oncol. 2019;15(5):e59–67.CrossRefPubMed Moghoofei M, Keshavarz M, Ghorbani S, Babaei F, Nahand JS, Tavakoli A, et al. Association between human papillomavirus infection and prostate cancer: a global systematic review and meta-analysis. Asia Pac J Clin Oncol. 2019;15(5):e59–67.CrossRefPubMed
4.
go back to reference Yin B, Liu W, Yu P, Liu C, Chen Y, Duan X, et al. Association between human papillomavirus and prostate cancer: a meta-analysis. Oncol Lett. 2017;14(2):1855–65.CrossRefPubMedPubMedCentral Yin B, Liu W, Yu P, Liu C, Chen Y, Duan X, et al. Association between human papillomavirus and prostate cancer: a meta-analysis. Oncol Lett. 2017;14(2):1855–65.CrossRefPubMedPubMedCentral
5.
6.
go back to reference Khatami A, Nahand JS, Kiani SJ, Khoshmirsafa M, Moghoofei M, Khanaliha K, et al. Human papilloma virus (HPV) and prostate cancer (PCa): the potential role of HPV gene expression and selected cellular MiRNAs in PCa development. Microb Pathog. 2022;166:105503.CrossRefPubMed Khatami A, Nahand JS, Kiani SJ, Khoshmirsafa M, Moghoofei M, Khanaliha K, et al. Human papilloma virus (HPV) and prostate cancer (PCa): the potential role of HPV gene expression and selected cellular MiRNAs in PCa development. Microb Pathog. 2022;166:105503.CrossRefPubMed
7.
go back to reference Sadri Nahand J, Esghaei M, Hamidreza Monavari S, Moghoofei M, Jalal Kiani S, Mostafaei S, et al. The assessment of a possible link between HPV-mediated inflammation, apoptosis, and angiogenesis in Prostate cancer. Int Immunopharmacol. 2020;88:106913.CrossRefPubMed Sadri Nahand J, Esghaei M, Hamidreza Monavari S, Moghoofei M, Jalal Kiani S, Mostafaei S, et al. The assessment of a possible link between HPV-mediated inflammation, apoptosis, and angiogenesis in Prostate cancer. Int Immunopharmacol. 2020;88:106913.CrossRefPubMed
8.
9.
go back to reference Cancer Genome Atlas Research. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011–25.CrossRef Cancer Genome Atlas Research. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011–25.CrossRef
10.
go back to reference Li J, Xu C, Lee HJ, Ren S, Zi X, Zhang Z, et al. A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature. 2020;580(7801):93–9.CrossRefPubMed Li J, Xu C, Lee HJ, Ren S, Zi X, Zhang Z, et al. A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature. 2020;580(7801):93–9.CrossRefPubMed
11.
go back to reference Tian R, Cui Z, He D, Tian X, Gao Q, Ma X, et al. Risk stratification of cervical lesions using capture sequencing and machine learning method based on HPV and human integrated genomic profiles. Carcinogenesis. 2019;40(10):1220–8.CrossRefPubMed Tian R, Cui Z, He D, Tian X, Gao Q, Ma X, et al. Risk stratification of cervical lesions using capture sequencing and machine learning method based on HPV and human integrated genomic profiles. Carcinogenesis. 2019;40(10):1220–8.CrossRefPubMed
12.
go back to reference Tian R, Wang Y, Li W, Cui Z, Pan T, Jin Z, et al. Genome-wide virus-integration analysis reveals a common insertional mechanism of HPV, HBV and EBV. Clin Transl Med. 2022;12(8):e971.CrossRefPubMedPubMedCentral Tian R, Wang Y, Li W, Cui Z, Pan T, Jin Z, et al. Genome-wide virus-integration analysis reveals a common insertional mechanism of HPV, HBV and EBV. Clin Transl Med. 2022;12(8):e971.CrossRefPubMedPubMedCentral
13.
go back to reference Vasimuddin M, Misra S, Li H, Aluru S. Efficient architecture-aware acceleration of BWA-MEM for multicore systems. In: 2019 IEEE international parallel and distributed processing symposium (IPDPS) 2019. p. 314–24. Vasimuddin M, Misra S, Li H, Aluru S. Efficient architecture-aware acceleration of BWA-MEM for multicore systems. In: 2019 IEEE international parallel and distributed processing symposium (IPDPS) 2019. p. 314–24.
14.
go back to reference Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.CrossRefPubMedPubMedCentral Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.CrossRefPubMedPubMedCentral
15.
go back to reference Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics (Oxf, Engl). 2009;25(16):2078–9.CrossRef Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics (Oxf, Engl). 2009;25(16):2078–9.CrossRef
16.
go back to reference DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491–8.CrossRefPubMedPubMedCentral DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491–8.CrossRefPubMedPubMedCentral
17.
go back to reference Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213–9.CrossRefPubMedPubMedCentral Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213–9.CrossRefPubMedPubMedCentral
18.
go back to reference Mayakonda A, Lin D-C, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–56.CrossRefPubMedPubMedCentral Mayakonda A, Lin D-C, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–56.CrossRefPubMedPubMedCentral
19.
go back to reference Shen R, Seshan VE. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016;44(16):e131.CrossRefPubMedPubMedCentral Shen R, Seshan VE. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016;44(16):e131.CrossRefPubMedPubMedCentral
20.
go back to reference Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.CrossRefPubMedPubMedCentral Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.CrossRefPubMedPubMedCentral
21.
go back to reference Sondka Z, Bamford S, Cole CG, Ward SA, Dunham I, Forbes SA. The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat Rev Cancer. 2018;18(11):696–705.CrossRefPubMedPubMedCentral Sondka Z, Bamford S, Cole CG, Ward SA, Dunham I, Forbes SA. The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat Rev Cancer. 2018;18(11):696–705.CrossRefPubMedPubMedCentral
22.
go back to reference Steven MC, Rohith TN, Ryan DS, Jordan R, Mustafa K, Jordan GB, et al. Non-oncology drugs are a source of previously unappreciated anti-cancer activity. bioRxiv. 2019:730119. Steven MC, Rohith TN, Ryan DS, Jordan R, Mustafa K, Jordan GB, et al. Non-oncology drugs are a source of previously unappreciated anti-cancer activity. bioRxiv. 2019:730119.
23.
go back to reference de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70.CrossRefPubMedPubMedCentral de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70.CrossRefPubMedPubMedCentral
25.
go back to reference Zhang J, Tian X, Chen Y, Huang S, Cui Z, Tian R, et al. Feasibility and accuracy of menstrual blood testing for high-risk human papillomavirus detection with capture sequencing. JAMA Netw Open. 2021;4(12):e2140644.CrossRefPubMedPubMedCentral Zhang J, Tian X, Chen Y, Huang S, Cui Z, Tian R, et al. Feasibility and accuracy of menstrual blood testing for high-risk human papillomavirus detection with capture sequencing. JAMA Netw Open. 2021;4(12):e2140644.CrossRefPubMedPubMedCentral
26.
go back to reference Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat J-P, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44(6):685–9.CrossRefPubMedPubMedCentral Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat J-P, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44(6):685–9.CrossRefPubMedPubMedCentral
27.
go back to reference Hjorth-Jensen K, Maya-Mendoza A, Dalgaard N, Sigurðsson JO, Bartek J, Iglesias-Gato D, et al. SPOP promotes transcriptional expression of DNA repair and replication factors to prevent replication stress and genomic instability. Nucleic Acids Res. 2018;46(18):9484–95.CrossRefPubMedPubMedCentral Hjorth-Jensen K, Maya-Mendoza A, Dalgaard N, Sigurðsson JO, Bartek J, Iglesias-Gato D, et al. SPOP promotes transcriptional expression of DNA repair and replication factors to prevent replication stress and genomic instability. Nucleic Acids Res. 2018;46(18):9484–95.CrossRefPubMedPubMedCentral
28.
go back to reference Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2019;571(7765):408–12.CrossRefPubMedPubMedCentral Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2019;571(7765):408–12.CrossRefPubMedPubMedCentral
29.
go back to reference Zhai X, Brownell JE. Biochemical perspectives on targeting KMT2 methyltransferases in cancer. Trends Pharmacol Sci. 2021;42(8):688–99.CrossRefPubMed Zhai X, Brownell JE. Biochemical perspectives on targeting KMT2 methyltransferases in cancer. Trends Pharmacol Sci. 2021;42(8):688–99.CrossRefPubMed
30.
go back to reference Liu Y, Hu Y, Zhang M, Jiang R, Liang C. Polymorphisms in ERCC2 and ERCC5 and risk of prostate cancer: a meta-analysis and systematic review. J Cancer. 2018;9(16):2786–94.CrossRefPubMedPubMedCentral Liu Y, Hu Y, Zhang M, Jiang R, Liang C. Polymorphisms in ERCC2 and ERCC5 and risk of prostate cancer: a meta-analysis and systematic review. J Cancer. 2018;9(16):2786–94.CrossRefPubMedPubMedCentral
31.
go back to reference Albacker LA, Wu J, Smith P, Warmuth M, Stephens PJ, Zhu P, et al. Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. PLoS ONE. 2017;12(11):e0176181.CrossRefPubMedPubMedCentral Albacker LA, Wu J, Smith P, Warmuth M, Stephens PJ, Zhu P, et al. Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. PLoS ONE. 2017;12(11):e0176181.CrossRefPubMedPubMedCentral
32.
go back to reference Bagherabadi A, Hooshmand A, Shekari N, Singh P, Zolghadri S, Stanek A, et al. Correlation of NTRK1 downregulation with low levels of tumor-infiltrating immune cells and poor prognosis of prostate cancer revealed by gene network analysis. Genes (Basel). 2022;13(5):840.CrossRefPubMedPubMedCentral Bagherabadi A, Hooshmand A, Shekari N, Singh P, Zolghadri S, Stanek A, et al. Correlation of NTRK1 downregulation with low levels of tumor-infiltrating immune cells and poor prognosis of prostate cancer revealed by gene network analysis. Genes (Basel). 2022;13(5):840.CrossRefPubMedPubMedCentral
33.
go back to reference González IA, Stewart DR, Schultz KAP, Field AP, Hill DA, Dehner LP. DICER1 tumor predisposition syndrome: an evolving story initiated with the pleuropulmonary blastoma. Mod Pathol. 2022;35(1):4–22.CrossRefPubMed González IA, Stewart DR, Schultz KAP, Field AP, Hill DA, Dehner LP. DICER1 tumor predisposition syndrome: an evolving story initiated with the pleuropulmonary blastoma. Mod Pathol. 2022;35(1):4–22.CrossRefPubMed
34.
go back to reference Mizuno K, Beltran H. Future directions for precision oncology in prostate cancer. Prostate. 2022;82(Suppl 1):S86–96.PubMed Mizuno K, Beltran H. Future directions for precision oncology in prostate cancer. Prostate. 2022;82(Suppl 1):S86–96.PubMed
35.
go back to reference Crocetto F, Barone B, Caputo VF, Fontana M, de Cobelli O, Ferro M. BRCA germline mutations in prostate cancer: the future is tailored. Diagnostics (Basel). 2021;11(5):908.CrossRefPubMed Crocetto F, Barone B, Caputo VF, Fontana M, de Cobelli O, Ferro M. BRCA germline mutations in prostate cancer: the future is tailored. Diagnostics (Basel). 2021;11(5):908.CrossRefPubMed
36.
go back to reference Crocetto F, Russo G, Di Zazzo E, Pisapia P, Mirto BF, Palmieri A, et al. Liquid biopsy in prostate cancer management-current challenges and future perspectives. Cancers (Basel). 2022;14(13):3272.CrossRefPubMedPubMedCentral Crocetto F, Russo G, Di Zazzo E, Pisapia P, Mirto BF, Palmieri A, et al. Liquid biopsy in prostate cancer management-current challenges and future perspectives. Cancers (Basel). 2022;14(13):3272.CrossRefPubMedPubMedCentral
Metadata
Title
Genomic alterations related to HPV infection status in a cohort of Chinese prostate cancer patients
Authors
Bin Lang
Chen Cao
Xiaoxiao Zhao
Yi Wang
Ying Cao
Xueying Zhou
Tong Zhao
Yuyan Wang
Ting Liu
Wenjia Liang
Zheng Hu
Xun Tian
Jingjing Zhang
Yongji Yan
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01207-2

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue